Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch

CNS Neuroscience and Therapeutics

Volumn 16, Issue 1, 2010, Pages 51-60

  Sadowsky, C ^a   Perez, J A Davila ^b   Bouchard, R W ^c   Goodman, I ^d   Tekin, S ^e  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b Médico Neurólogo Policlínica Santiago de León ^*  (Venezuela)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Switching; Transdermal

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE;

ABSCESS; ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; ANEMIA; APPLICATION SITE IRRITATION; APPLICATION SITE REACTION; BEHAVIOR DISORDER; BRADYCARDIA; CASE STUDY; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONSTIPATION; DATA BASE; DECREASED APPETITE; DEHYDRATION; DEMENTIA; DRUG CAPSULE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FALLING; FATIGUE; HALLUCINATION; HIP FRACTURE; HUMAN; HYPERTENSION; IRRITANT DERMATITIS; LETHARGY; LOW DRUG DOSE; MEDICAL LITERATURE; MEDLINE; MENTAL HEALTH; NAUSEA; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; OPEN STUDY; PRACTICE GUIDELINE; RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TRANSDERMAL PATCH; VAGINA TUMOR; VOMITING;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DATABASES, FACTUAL; FEMALE; HUMANS; INDANS; MALE; PHENYLCARBAMATES; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 74549225588     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2009.00119.x     Document Type: Review

References (38)

1. Rosenstein LD. Differential diagnosis of the major progressive dementias and depression in middle and late adulthood: A summary of the literature of the early 1990s. Neuropsychol Rev 1998 8 : 109 167.
2. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976 2 : 1403.
3. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology 1996 47 : 876 883.
4. Doody RS, Stevens JC, Beck C, et al. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001 56 : 1154 1166.
5. Enz A, Boddeke H, Gray J, Spiegel R. Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. Ann N Y Acad Sci 1991 640 : 272 275.
6. Bickel U, Thomsen T, Fischer JP, Weber W, Kewitz H. Galanthamine: Pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 1991 30 : 447 454.
7. Kasa P, Papp H, Kasa P, Jr., Torok I. Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain. Neuroscience 2000 101 : 89 100.
8. Poirier J. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl 2002 127 : 6 19.
9. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002 127 : 45 63.
10. Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: Potential benefits of a transdermal patch. Curr Med Res Opin 2007 23 : 2705 2713.
11. Nitti VW, Sanders S, Staskin DR, Dmochowski RR, Sand PK, MacDiarmid S, Maibach H. Transdermal delivery of drugs for urologic applications: Basic principles and applications. Urology 2006 67 : 657 664.
12. Priano L, Gasco MR, Mauro A. Transdermal treatment options for neurological disorders: Impact on the elderly. Drugs Aging 2006 23 : 357 375.
13. Winblad B, Machado JC. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. Expert Opin Drug Deliv 2008 5 : 1377 1386.
14. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: A review. Int J Clin Pract 2009 63 : 799 805.
15. Mercier F, Lefèvre G, Huang HL, Schmidli H, Amzal B, Appel-Dingemanse S. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin 2007 23 : 3199 3204.
16. Cummings J, Lefèvre G, Small G, Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007 69 : S10 S13.
17. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 2001 15 : 375 390.
18. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002 41 : 719 739.
19. Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer's disease: Is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001 16 : 653 666.
20. Gauthier S. Long-term efficacy of cholinesterase inhibitors. Brain Aging 2002 2 : 9 22.
21. Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer's disease: Switching cholinesterase inhibitors. Curr Med Res Opin 2003 19 : 707 714. (Pubitemid 37466140)
22. Farlow MR. Pharmacokinetic profiles of current therapies for Alzheimer's disease: Implications for switching to galantamine. Clin Ther 2001 23 : A13 A24.
23. Bullock R, Connolly C. Switching cholinesterase inhibitor therapy in Alzheimer's disease - donepezil to rivastigmine, is it worth it? Int J Geriatr Psychiatry 2002 17 : 288 289.
24. Cummings J, Winblad B. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Rev Neurother 2007 7 : 1457 1463. (Pubitemid 350106826)
25. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007 22 : 456 467.
26. Lefèvre G, Sedek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 2008 83 : 106 114.
27. Grossberg G, Sadowsky C, Forstl H, et al. Safety and tolerability of the rivastigmine patch: Results of a 28-week open-label extension. Alzheimer Dis Assoc Disord 2009 23 : 158 164.
28. Shua-Haim J, Yap C, Kretov A, Lee P. Results of next day crossover study of donepezil (Aricept) to rivastigmine patch (Exelon Patch) in Alzheimer's disease patients: A two-month clinical experience. Poster presented at the International Conference on Alzheimer's Disease 2008 Chicago, IL, USA.
29. Shua-Haim J, Yap C, Kretov A, Lee P. Results of next-day crossover study of rivastigmine oral capsules (Exelon) to rivastigmine patch (Exelon Patch) in Alzheimer's disease patients: A two-month clinical experience. Poster presented at the International Conference on Alzheimer's Disease 2008 Chicago, IL, USA.
30. Shua-Haim J, Yap C, Kretov A, Lee P. Results of a two-step crossover study of donepezil (Aricept) to rivastigmine patch (Exelon Patch) in Alzheimer's disease patients: A two-month clinical experience. Poster presented at the International Conference on Alzheimer's Disease 2008 Chicago, IL, USA.
31. Shua-Haim J, Yap C, Kretov A, Lee P, Patel S. Results of next-day crossover study of galantamine ER (Razadyne ER) to rivastigmine patch (Exelon Patch) in Alzheimer's disease patients: A two-month clinical experience. Poster presented at the International Conference on Alzheimer's Disease 2008 Chicago, IL, USA.
32. Sadowsky CH DA, Olin JT, Koumaras B. Meng X, Brannan S, on behalf of the US38 Study Group. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. Am J Alz Dis Other Dement 2009 24 : 267 275.
33. Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology. Drug Saf 1998 19 : 465 480.
34. Summary of product characteristics : Exelon 4.6 mg/24 h and 9.5 mg/24 h transdermal patch. May 2008.
35. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007 68 : 1262 1267.
36. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: A double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002 159 : 1869 1875.
37. Wolf R, Tuzun B, Tuzun Y. Adverse skin reactions to the nicotine transdermal system. Clin Dermatol 1998 16 : 617 623.
38. Ale I, Lachapelle J-M, Maibach HI. Skin tolerability associated with transdermal drug delivery systems: An overview. Adv Ther 2009 26 : 920 935.